Hematological Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Jadenu Approved for Chronic Iron Overload

The FDA has approved Jadenu (deferasirox) tablets for the treatment of chronic iron overload due to blood transfusions in patients ≥2 years old, and for chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients ≥10 years old.

Worse Outcomes With Anemia, Anticoagulants

For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality.

Old Blood As Good As Fresh?

Blood that's been stored for a few weeks is just as beneficial as fresh blood for patients with life-threatening conditions who require transfusions, a new study shows.

Comparing ESAs for Anemia

Is one erythropoiesis-stimulating agent (ESA) superior to others for treating anemia in patients with chronic kidney disease (CKD)?

First-in-Class Tx for Rare Leukemia

The FDA has approved Blincyto (blinatumomab) for the treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.

Erwinaze Approved for IV Route

Jazz Pharmaceuticals announced that the FDA has approved the IV administration of Erwinaze (asparaginase Erwinia chrysantheum).

Fast Tracked Sickle Cell Disease Agent

NKT Therapeutics announced that the Food and Drug Administration (FDA) has granted Fast Track designation to NKTT120 for the treatment of sickle cell disease.

Blood Type and Cognitive Impairment Risk

Blood group AB and higher factor VIII are associated with increased incidence of cognitive impairment.

Featured courses from mycme

The Brigham Board Review in Hematology and OncologyExternal web site

The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...

CME 42.00 Credits

Infectious Disease, Endocrine, Hematologic and Derm SystemsExternal web site

This module reviews all topics on the NCCPA examination blueprint relating to the Infectious Disease, ...

CME 6.25 Credits

Treating a Relapsed/Refractory 63-Year-Old Male With Emerging Agents in CLLExternal web site

This case will follow a patient from diagnosis through the third-line treatment decision. Optimal management ...

CME|CE 0.50 Credits

Sign Up for Free e-newsletters